Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody
Acute rejection episodes adversely affect short-term survival in recipients of cardiac transplants. 1 Rejection occurs most frequently during the first three months after transplantation, with the incidence decreasing exponentially thereafter. 2 Repeated or severe episodes of allograft rejection may...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2000-03, Vol.342 (9), p.613-619 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 619 |
|---|---|
| container_issue | 9 |
| container_start_page | 613 |
| container_title | The New England journal of medicine |
| container_volume | 342 |
| creator | Beniaminovitz, Ainat Itescu, Silviu Lietz, Katherine Donovan, Mary Burke, Elizabeth M Groff, Barbara D Edwards, Niloo Mancini, Donna M |
| description | Acute rejection episodes adversely affect short-term survival in recipients of cardiac transplants.
1
Rejection occurs most frequently during the first three months after transplantation, with the incidence decreasing exponentially thereafter.
2
Repeated or severe episodes of allograft rejection may lead to the development of cardiac-allograft vasculopathy, the main cause of death after the first year in transplant recipients.
3
–
6
Accordingly, therapeutic strategies, such as the use of induction therapy with monoclonal or polyclonal antibodies in the perioperative period, have been advocated to decrease the frequency and severity of early allograft rejection.
7
The success of these nonselective agents has varied.
7
Allograft rejection is . . . |
| doi_str_mv | 10.1056/NEJM200003023420902 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70916576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17499621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-bdefa24343ff869d6fdf7c93fbc6fb97a8564829e5df5480101cc47deb4ab97d3</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYModlv9BIIEkb7I1PybZPJYl2orrYrU5yGT3NDZziRrMmPZb2-2u1ARqXkJ4f7OuffmIPSKkhNKavn-y9nnK0bK4YRxwYgm7Ala0JrzSggin6IFIayphNL8AB3mvNqyVOjn6IASqTWVZIHuviX4BWHqY8DR4--wAnv_6ANemuR6Y_F1MiGvBxMmc1_qNvjDEO2tcbDVTDeAL8IEaYD5tg8VKy4W1lNM-K6fbrDBVzFEO8RgBnxaWnXRbV6gZ94MGV7u7yP04-PZ9fK8uvz66WJ5elnZupZT1TnwhgkuuPeN1E5655XV3HdW-k4r09RSNExD7XwtGkIJtVYoB50wpez4ETre-a5T_DlDntqxzxaGsg3EObeKlH-olfwvSJXQWjJawDd_gas4p7JbbhnjmotG8QLxHWRTzDmBb9epH03atJS02_Taf6RXVK_31nM3gvtDs4urAG_3gMnWDL4EY_v8wLGGqGY74rsdNo65DbAaH-36G0HLrmI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223934873</pqid></control><display><type>article</type><title>Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Beniaminovitz, Ainat ; Itescu, Silviu ; Lietz, Katherine ; Donovan, Mary ; Burke, Elizabeth M ; Groff, Barbara D ; Edwards, Niloo ; Mancini, Donna M</creator><creatorcontrib>Beniaminovitz, Ainat ; Itescu, Silviu ; Lietz, Katherine ; Donovan, Mary ; Burke, Elizabeth M ; Groff, Barbara D ; Edwards, Niloo ; Mancini, Donna M</creatorcontrib><description>Acute rejection episodes adversely affect short-term survival in recipients of cardiac transplants.
1
Rejection occurs most frequently during the first three months after transplantation, with the incidence decreasing exponentially thereafter.
2
Repeated or severe episodes of allograft rejection may lead to the development of cardiac-allograft vasculopathy, the main cause of death after the first year in transplant recipients.
3
–
6
Accordingly, therapeutic strategies, such as the use of induction therapy with monoclonal or polyclonal antibodies in the perioperative period, have been advocated to decrease the frequency and severity of early allograft rejection.
7
The success of these nonselective agents has varied.
7
Allograft rejection is . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200003023420902</identifier><identifier>PMID: 10699160</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Acute Disease ; Adult ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Cytokines ; Disease-Free Survival ; Female ; Graft Rejection - prevention & control ; Heart Transplantation - immunology ; Histocompatibility Testing ; Humans ; Immunoglobulin G - adverse effects ; Immunoglobulin G - therapeutic use ; immunoglobulin G1 ; Immunomodulators ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; interleukin 2 receptors ; Male ; Medical sciences ; Middle Aged ; Patients ; Pharmacology. Drug treatments ; Receptors, Interleukin-2 - antagonists & inhibitors ; Transplantation Immunology ; Transplants & implants</subject><ispartof>The New England journal of medicine, 2000-03, Vol.342 (9), p.613-619</ispartof><rights>Copyright © 2000 Massachusetts Medical Society. All rights reserved.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c556t-bdefa24343ff869d6fdf7c93fbc6fb97a8564829e5df5480101cc47deb4ab97d3</citedby><cites>FETCH-LOGICAL-c556t-bdefa24343ff869d6fdf7c93fbc6fb97a8564829e5df5480101cc47deb4ab97d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200003023420902$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223934873?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,2760,2761,26108,27929,27930,52387,54069,64390,64392,64394,72474</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1280781$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10699160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beniaminovitz, Ainat</creatorcontrib><creatorcontrib>Itescu, Silviu</creatorcontrib><creatorcontrib>Lietz, Katherine</creatorcontrib><creatorcontrib>Donovan, Mary</creatorcontrib><creatorcontrib>Burke, Elizabeth M</creatorcontrib><creatorcontrib>Groff, Barbara D</creatorcontrib><creatorcontrib>Edwards, Niloo</creatorcontrib><creatorcontrib>Mancini, Donna M</creatorcontrib><title>Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Acute rejection episodes adversely affect short-term survival in recipients of cardiac transplants.
1
Rejection occurs most frequently during the first three months after transplantation, with the incidence decreasing exponentially thereafter.
2
Repeated or severe episodes of allograft rejection may lead to the development of cardiac-allograft vasculopathy, the main cause of death after the first year in transplant recipients.
3
–
6
Accordingly, therapeutic strategies, such as the use of induction therapy with monoclonal or polyclonal antibodies in the perioperative period, have been advocated to decrease the frequency and severity of early allograft rejection.
7
The success of these nonselective agents has varied.
7
Allograft rejection is . . .</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Cytokines</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Graft Rejection - prevention & control</subject><subject>Heart Transplantation - immunology</subject><subject>Histocompatibility Testing</subject><subject>Humans</subject><subject>Immunoglobulin G - adverse effects</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>immunoglobulin G1</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>interleukin 2 receptors</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Interleukin-2 - antagonists & inhibitors</subject><subject>Transplantation Immunology</subject><subject>Transplants & implants</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkV9rFDEUxYModlv9BIIEkb7I1PybZPJYl2orrYrU5yGT3NDZziRrMmPZb2-2u1ARqXkJ4f7OuffmIPSKkhNKavn-y9nnK0bK4YRxwYgm7Ala0JrzSggin6IFIayphNL8AB3mvNqyVOjn6IASqTWVZIHuviX4BWHqY8DR4--wAnv_6ANemuR6Y_F1MiGvBxMmc1_qNvjDEO2tcbDVTDeAL8IEaYD5tg8VKy4W1lNM-K6fbrDBVzFEO8RgBnxaWnXRbV6gZ94MGV7u7yP04-PZ9fK8uvz66WJ5elnZupZT1TnwhgkuuPeN1E5655XV3HdW-k4r09RSNExD7XwtGkIJtVYoB50wpez4ETre-a5T_DlDntqxzxaGsg3EObeKlH-olfwvSJXQWjJawDd_gas4p7JbbhnjmotG8QLxHWRTzDmBb9epH03atJS02_Taf6RXVK_31nM3gvtDs4urAG_3gMnWDL4EY_v8wLGGqGY74rsdNo65DbAaH-36G0HLrmI</recordid><startdate>20000302</startdate><enddate>20000302</enddate><creator>Beniaminovitz, Ainat</creator><creator>Itescu, Silviu</creator><creator>Lietz, Katherine</creator><creator>Donovan, Mary</creator><creator>Burke, Elizabeth M</creator><creator>Groff, Barbara D</creator><creator>Edwards, Niloo</creator><creator>Mancini, Donna M</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000302</creationdate><title>Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody</title><author>Beniaminovitz, Ainat ; Itescu, Silviu ; Lietz, Katherine ; Donovan, Mary ; Burke, Elizabeth M ; Groff, Barbara D ; Edwards, Niloo ; Mancini, Donna M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-bdefa24343ff869d6fdf7c93fbc6fb97a8564829e5df5480101cc47deb4ab97d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Cytokines</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Graft Rejection - prevention & control</topic><topic>Heart Transplantation - immunology</topic><topic>Histocompatibility Testing</topic><topic>Humans</topic><topic>Immunoglobulin G - adverse effects</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>immunoglobulin G1</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>interleukin 2 receptors</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Interleukin-2 - antagonists & inhibitors</topic><topic>Transplantation Immunology</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beniaminovitz, Ainat</creatorcontrib><creatorcontrib>Itescu, Silviu</creatorcontrib><creatorcontrib>Lietz, Katherine</creatorcontrib><creatorcontrib>Donovan, Mary</creatorcontrib><creatorcontrib>Burke, Elizabeth M</creatorcontrib><creatorcontrib>Groff, Barbara D</creatorcontrib><creatorcontrib>Edwards, Niloo</creatorcontrib><creatorcontrib>Mancini, Donna M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>Proquest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beniaminovitz, Ainat</au><au>Itescu, Silviu</au><au>Lietz, Katherine</au><au>Donovan, Mary</au><au>Burke, Elizabeth M</au><au>Groff, Barbara D</au><au>Edwards, Niloo</au><au>Mancini, Donna M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2000-03-02</date><risdate>2000</risdate><volume>342</volume><issue>9</issue><spage>613</spage><epage>619</epage><pages>613-619</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Acute rejection episodes adversely affect short-term survival in recipients of cardiac transplants.
1
Rejection occurs most frequently during the first three months after transplantation, with the incidence decreasing exponentially thereafter.
2
Repeated or severe episodes of allograft rejection may lead to the development of cardiac-allograft vasculopathy, the main cause of death after the first year in transplant recipients.
3
–
6
Accordingly, therapeutic strategies, such as the use of induction therapy with monoclonal or polyclonal antibodies in the perioperative period, have been advocated to decrease the frequency and severity of early allograft rejection.
7
The success of these nonselective agents has varied.
7
Allograft rejection is . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>10699160</pmid><doi>10.1056/NEJM200003023420902</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2000-03, Vol.342 (9), p.613-619 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70916576 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Acute Disease Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Cytokines Disease-Free Survival Female Graft Rejection - prevention & control Heart Transplantation - immunology Histocompatibility Testing Humans Immunoglobulin G - adverse effects Immunoglobulin G - therapeutic use immunoglobulin G1 Immunomodulators Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use interleukin 2 receptors Male Medical sciences Middle Aged Patients Pharmacology. Drug treatments Receptors, Interleukin-2 - antagonists & inhibitors Transplantation Immunology Transplants & implants |
| title | Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T04%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20Rejection%20in%20Cardiac%20Transplantation%20by%20Blockade%20of%20the%20Interleukin-2%20Receptor%20with%20a%20Monoclonal%20Antibody&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Beniaminovitz,%20Ainat&rft.date=2000-03-02&rft.volume=342&rft.issue=9&rft.spage=613&rft.epage=619&rft.pages=613-619&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM200003023420902&rft_dat=%3Cproquest_cross%3E17499621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223934873&rft_id=info:pmid/10699160&rfr_iscdi=true |